Novo Nordisk Patent Expiry Boosts Cheaper Drugs in India

The expiration of Novo Nordisk's patent on semaglutide in India is poised to disrupt the market for diabetes and weight-loss medications. This development will allow local manufacturers to introduce more affordable generic versions of the popular drug. However, the influx of generics raises concerns about regulatory oversight and quality control within India's increasingly crowded pharmaceutical landscape, potentially leading to market volatility.